Asia-Pacific Lung Transplant Therapeutics Market to 2032
Overview
The Asia-Pacific Lung Transplant Therapeutics Market is expected to reach a 34.33 USD Million by 2032 and is projected to grow at a CAGR of 3.98% from 2025 to 2032.
Revenue, 2024 (USD Million)
26.81
Forecast, 2032 (USD Million)
34.33
CAGR, 2024 - 2032
3.98%
Report Coverage
Asia-Pacific
Asia-Pacific Lung Transplant Therapeutics Market 2018-2032 USD Million
Asia-Pacific Lung Transplant Therapeutics Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 26.81 USD Million
- Projected Market Size (2032): 34.33 USD Million
- CAGR (2025-2032): 3.98%
Key Findings of Asia-Pacific Lung Transplant Therapeutics Market
- The Asia-Pacific Lung Transplant Therapeutics Market was valued at 26.81 USD Million in 2024.
- The Asia-Pacific Lung Transplant Therapeutics Market is likely to grow at a CAGR of 3.98% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Cadaveric Lung Transplant in Type Segment accounted for the largest share of the market with a revenue of 25.82 USD Million
- The fastest growing segment Cystic Fibrosis in Indication Segment grew Fastest with a CAGR of 5.98% during the forecast period from 2024 to 2032.
Asia-Pacific Lung Transplant Therapeutics Market Scope
Asia-Pacific Lung Transplant Therapeutics Market Segmentation & Scope
Product
- Others
- Tissue Product
- Organ Preservation Products
- Immunosuppressant Drugs
Indication
- Others
- Septic Lung disease
- Sarcoidosis
- Emphysema
- Primary Pulmonary Arterial Hypertension
- Pulmonary Hypertension
- Interstitial pulmonary fibrosis
- Chronic Obstructive Pulmonary Disease (COPD)
- Pulmonary Fibrosis
- Cystic Fibrosis
Type
- Living Lung Transplant
- Cadaveric Lung Transplant
Technique
- Heart-Lung Transplant
- Bilateral Lung Transplant (BLT)
- Double Lung Transplant
- Single-Lung Transplant (SLT)
Patient Demographics
- Pediatric
- Geriatric
- Adults
End Users
- Others
- Specialty Centers
- Transplant Centers
- Hospital
Asia-Pacific Lung Transplant Therapeutics Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2022 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 26.81 USD Million |
| Market Value in 2032 | 34.33 USD Million |
| CAGR (2025-2032) | 3.98% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Product,Indication,Type,Technique,Patient Demographics,End Users |
Regional Insights:
-
Leading Market (2024-2032): Asia-Pacific, leading in terms of revenue 26.81 USD Million in 2024
- Key Country: China, leading in terms of revenue with value of 12.67 USD Million in 2024.
Segments and Scope
-
Asia-Pacific Lung Transplant Therapeutics Market to 2032, By Product
- Immunosuppressant Drugs is the largest segment in Asia-Pacific Lung Transplant Therapeutics Market to 2032 with a revenue of 21.17 USD Million in the year 2024.
- Immunosuppressant Drugs is the Fastest growing segment in Asia-Pacific Lung Transplant Therapeutics Market to 2032 with a Growth rate of 4.17 % in forecast period 2025-2032.
-
Asia-Pacific Lung Transplant Therapeutics Market to 2032, By Indication
- Cystic Fibrosis is the largest segment in Asia-Pacific Lung Transplant Therapeutics Market to 2032 with a revenue of 8.72 USD Million in the year 2024.
- Cystic Fibrosis is the Fastest growing segment in Asia-Pacific Lung Transplant Therapeutics Market to 2032 with a Growth rate of 5.98 % in forecast period 2025-2032.
-
Asia-Pacific Lung Transplant Therapeutics Market to 2032, By Type
- Cadaveric Lung Transplant is the largest segment in Asia-Pacific Lung Transplant Therapeutics Market to 2032 with a revenue of 25.82 USD Million in the year 2024.
- Cadaveric Lung Transplant is the Fastest growing segment in Asia-Pacific Lung Transplant Therapeutics Market to 2032 with a Growth rate of 4.10 % in forecast period 2025-2032.
-
Asia-Pacific Lung Transplant Therapeutics Market to 2032, By Technique
- Single-Lung Transplant (SLT) is the largest segment in Asia-Pacific Lung Transplant Therapeutics Market to 2032 with a revenue of 16.14 USD Million in the year 2024.
- Single-Lung Transplant (SLT) is the Fastest growing segment in Asia-Pacific Lung Transplant Therapeutics Market to 2032 with a Growth rate of 4.54 % in forecast period 2025-2032.
-
Asia-Pacific Lung Transplant Therapeutics Market to 2032, By Patient Demographics
- Adults is the largest segment in Asia-Pacific Lung Transplant Therapeutics Market to 2032 with a revenue of 15.34 USD Million in the year 2024.
- Adults is the Fastest growing segment in Asia-Pacific Lung Transplant Therapeutics Market to 2032 with a Growth rate of 4.39 % in forecast period 2025-2032.
-
Asia-Pacific Lung Transplant Therapeutics Market to 2032, By End Users
- Hospital is the largest segment in Asia-Pacific Lung Transplant Therapeutics Market to 2032 with a revenue of 19.03 USD Million in the year 2024.
- Hospital is the Fastest growing segment in Asia-Pacific Lung Transplant Therapeutics Market to 2032 with a Growth rate of 4.21 % in forecast period 2025-2032.
Asia-Pacific Lung Transplant Therapeutics Market Company Share Analysis
| Company Name |
|
||
| Viatris Inc. | |||
| ose-immuno | |||
| Panacea Biotec | |||
| Paragonix Technologies, Inc | |||
| NOVARTIS AG | |||
Asia-Pacific Lung Transplant Therapeutics Market Geographical Sales Distribution, 2018-2032 USD Million
Asia-Pacific Lung Transplant Therapeutics Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The Asia-Pacific Lung Transplant Therapeutics Market is segmented based on Segmentation Product,Indication,Type,Technique,Patient Demographics,End Users.
Asia-Pacific Lung Transplant Therapeutics Market was valued at USD 26.81(Revenue in USD Million) in 2022.
Asia-Pacific Lung Transplant Therapeutics Market is projected to grow at a CAGR of 3.98% during the forecast period of 2024 to 2032.
The Cadaveric Lung Transplant segment is expected to dominate the Asia-Pacific Lung Transplant Therapeutics Market, holding a largest market share of 25.82 USD Million in 2024
Asia-Pacific Lung Transplant Therapeutics Market Scope
Asia-Pacific Lung Transplant Therapeutics Market Segmentation & Scope
Product
- Others
- Tissue Product
- Organ Preservation Products
- Immunosuppressant Drugs
Indication
- Others
- Septic Lung disease
- Sarcoidosis
- Emphysema
- Primary Pulmonary Arterial Hypertension
- Pulmonary Hypertension
- Interstitial pulmonary fibrosis
- Chronic Obstructive Pulmonary Disease (COPD)
- Pulmonary Fibrosis
- Cystic Fibrosis
Type
- Living Lung Transplant
- Cadaveric Lung Transplant
Technique
- Heart-Lung Transplant
- Bilateral Lung Transplant (BLT)
- Double Lung Transplant
- Single-Lung Transplant (SLT)
Patient Demographics
- Pediatric
- Geriatric
- Adults
End Users
- Others
- Specialty Centers
- Transplant Centers
- Hospital
Frequently Asked Questions
The Asia-Pacific Lung Transplant Therapeutics Market is segmented based on Segmentation Product,Indication,Type,Technique,Patient Demographics,End Users.
Asia-Pacific Lung Transplant Therapeutics Market was valued at USD 26.81(Revenue in USD Million) in 2022.
Asia-Pacific Lung Transplant Therapeutics Market is projected to grow at a CAGR of 3.98% during the forecast period of 2024 to 2032.
The estimated market value of the Asia-Pacific Lung Transplant Therapeutics Market for final year is USD 34.33 (USD Million).
Asia-Pacific Lung Transplant Therapeutics Market Company Profiling
Frequently Asked Questions
The Asia-Pacific Lung Transplant Therapeutics Market is segmented based on Segmentation Product,Indication,Type,Technique,Patient Demographics,End Users.
Asia-Pacific Lung Transplant Therapeutics Market was valued at USD 26.81(Revenue in USD Million) in 2022.
Asia-Pacific Lung Transplant Therapeutics Market is projected to grow at a CAGR of 3.98% during the forecast period of 2024 to 2032.
The estimated market value of the Asia-Pacific Lung Transplant Therapeutics Market for final year is USD 34.33 (USD Million).
CHOOSE LICENCE TYPE
- 4200.00
- 3500.00
- 2000.00
- 5500.00
- 8500.00
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.